ENTX Insider Trading
Insider Ownership Percentage: 10.38%
Insider Buying (Last 12 Months): $19,910.00
Insider Selling (Last 12 Months): $0.00
Entera Bio Share Price & Price History
Current Price: $1.60
Price Change: ▲ Price Increase of +0.02 (1.27%)
As of 01/23/2026 05:00 PM ET
Entera Bio Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/29/2025 | Miranda Jayne Toledano | CEO | Buy | 11,000 | $1.81 | $19,910.00 | 426,575 |  |
| 1/12/2024 | Haya Taitel | Director | Buy | 9,500 | $0.99 | $9,405.00 | 35,115 | |
| 1/10/2024 | Haya Taitel | Director | Buy | 7,615 | $0.77 | $5,863.55 | 25,615 | |
| 12/22/2023 | Miranda Jayne Toledano | CEO | Buy | 23,952 | $0.71 | $17,005.92 | 110,752 | |
| 8/21/2023 | Sean Ellis | Director | Buy | 40,000 | $0.60 | $24,000.00 | 102,100 | |
| 4/4/2023 | Miranda Jayne Toledano | CEO | Buy | 30,000 | $1.01 | $30,300.00 | 86,800 | |
Entera Bio Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 11/17/2025 | Parkman Healthcare Partners LLC | 280,822 | $0.54M | 0.1% | -21.1% | 0.615% |  |
| 11/17/2025 | Citadel Advisors LLC | 39,978 | $77K | 0.0% | +243.0% | 0.088% | |
| 11/14/2025 | Schonfeld Strategic Advisors LLC | 566,956 | $1.09M | 0.0% | -6.2% | 1.242% | |
| 8/15/2025 | Bank of America Corp DE | 23,430 | $45K | 0.0% | -24.4% | 0.051% | |
| 8/1/2025 | Bessemer Group Inc. | 140,843 | $0.27M | 0.0% | N/A | 0.310% | |
| 5/16/2025 | Parkman Healthcare Partners LLC | 439,632 | $0.75M | 0.1% | +6.3% | 0.968% | |
| 5/13/2025 | HighTower Advisors LLC | 18,140 | $31K | 0.0% | +53.3% | 0.040% | |
| 2/18/2025 | Knoll Capital Management LLC | 5,881,879 | $12.47M | 8.0% | +51.5% | 16.439% | |
| 2/14/2025 | Schonfeld Strategic Advisors LLC | 632,311 | $1.34M | 0.0% | -2.5% | 1.767% | |
| 2/14/2025 | Northern Trust Corp | 212,483 | $0.45M | 0.0% | N/A | 0.594% | |
| 1/22/2025 | Perigon Wealth Management LLC | 145,843 | $0.33M | 0.0% | N/A | 0.408% | |
| 11/15/2024 | Parkman Healthcare Partners LLC | 411,076 | $0.78M | 0.1% | +2.4% | 1.149% | |
| 11/6/2024 | Signature Estate & Investment Advisors LLC | 47,328 | $90K | 0.0% | N/A | 0.132% | |
| 8/9/2024 | Renaissance Technologies LLC | 57,600 | $0.11M | 0.0% | -23.1% | 0.161% | |
| 5/20/2024 | Virtu Financial LLC | 22,040 | $37K | 0.0% | N/A | 0.000% | |
| 2/14/2023 | RA Capital Management L.P. | 295,966 | $0.22M | 0.0% | -85.8% | 1.028% | |
| 11/14/2022 | RA Capital Management L.P. | 2,082,372 | $2.17M | 0.0% | -11.5% | 7.229% | |
| 1/31/2022 | Altium Wealth Management LLC | 11,830 | $33K | 0.0% | N/A | 0.050% | |
| 1/28/2022 | ARK Investment Management LLC | 690,922 | $1.95M | 0.0% | +1.2% | 2.915% | |
Data available starting January 2016
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Read More on Entera Bio
Volume
176,566 shs
Average Volume
265,540 shs
Market Capitalization
$73.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.78
Who are the company insiders with the largest holdings of Entera Bio?
